Can I reduce the indapamide dose to 0.75 mg?

Can You Lower Indapamide to 0.75 mg?

No, you should not lower indapamide to 0.75 mg—this dose is not supported by any clinical evidence or FDA approval, and falls below the minimum effective dose established in clinical trials.

Standard Dosing According to FDA Label and Guidelines

The FDA-approved dosing for indapamide is clear and specific 1:

• For hypertension: Start at 1.25 mg once daily, may increase to 2.5 mg after 4 weeks if needed, maximum 5 mg daily
• For heart failure edema: Start at 2.5 mg once daily, may increase to 5 mg after 1 week if needed

Multiple international guidelines consistently recommend 2.5 mg as the standard initial dose for indapamide in both hypertension and heart failure 2, 3, 4, 5, 6, 4, 7. The 2018 ACC/AHA guidelines specify indapamide dosing as 1.25-2.5 mg for hypertension 8, while the 2025 AHA/ACC guidelines note that thiazide-like diuretics (including indapamide) at standard doses provide superior cardiovascular protection 9.

Clinical Evidence for Lower Doses

The lowest dose with proven efficacy is 1.25 mg daily, not 0.75 mg:

• A large randomized trial demonstrated that 1.25 mg once daily is as effective as 2.5 mg for blood pressure control in mild-to-moderate hypertension, with 74% of patients maintaining BP control when switched from 2.5 mg to 1.25 mg 10
• Two placebo-controlled trials with 417 patients confirmed that 1.25 mg is the minimum effective dose, producing statistically significant BP reductions compared to placebo 11
• In elderly patients (≥65 years), 1.25 mg once daily reduced BP by 8.2/10.1 mmHg versus placebo 12
• The sustained-release formulation at 1.5 mg showed equivalent efficacy to 2.5 mg immediate-release with improved safety 13

No clinical trials have evaluated 0.75 mg indapamide, and this dose would likely be subtherapeutic.

Safety Considerations at Lower Doses

The rationale for using lower doses relates to minimizing adverse effects, particularly hypokalemia:

• 1.25 mg has a superior safety profile compared to 2.5 mg, with less potassium loss (mean change -0.2 mEq/L vs -0.4 mEq/L) 10
• The sustained-release 1.5 mg formulation reduced the incidence of serum potassium <3.4 mmol/L by more than 50% compared to 2.5 mg immediate-release 13
• Severe hypokalemia requiring hospitalization occurs in only 0.8% of patients on indapamide, with most cases occurring in the first 16 weeks of therapy 14

Practical Recommendations

If you're considering dose reduction, here's the appropriate approach:

1. If the patient is on 2.5 mg: You can safely reduce to 1.25 mg once daily based on strong clinical evidence 10, 11

   • Monitor BP at 2-4 weeks to ensure continued control
   • Check electrolytes, particularly potassium, within 1-2 weeks

2. If the patient is already on 1.25 mg: Do not reduce further to 0.75 mg

   • If side effects are problematic, consider switching to the sustained-release formulation (1.5 mg SR) if available
   • If BP is well-controlled and you want to simplify the regimen, consider discontinuing the diuretic rather than using a subtherapeutic dose

3. Alternative strategies if concerned about diuretic effects:

   • Switch to sustained-release indapamide 1.5 mg (better tolerability) 13
   • Consider every-other-day dosing of 1 mg indapamide, which has shown efficacy in one small study 15, though this is not standard practice
   • Optimize other antihypertensive medications to potentially reduce or eliminate diuretic need

Common Pitfalls to Avoid

• Don't use arbitrary doses: Stick to evidence-based dosing (1.25 mg, 2.5 mg, or 5 mg)
• Don't assume lower is always better: While minimizing dose reduces side effects, going below the therapeutic threshold eliminates benefit
• Monitor appropriately: Check electrolytes and renal function 1-2 weeks after any dose change, especially in elderly patients or those with CKD 2, 4

The bottom line: 1.25 mg is the lowest evidence-based dose for indapamide. A dose of 0.75 mg has no supporting data and should not be used.